The current conceptualization of negative symptoms in schizophrenia
Tóm tắt
Negative symptoms have long been conceptualized as a core aspect of schizophrenia. They play a key role in the functional outcome of the disorder, and their management represents a significant unmet need. Improvements in definition, characterization, assessment instruments and experimental models are needed in order to foster research aimed at developing effective interventions. A consensus has recently been reached on the following aspects: a) five constructs should be considered as negative symptoms, i.e. blunted affect, alogia, anhedonia, asociality and avolition; b) for each construct, symptoms due to identifiable factors, such as medication effects, psychotic symptoms or depression, should be distinguished from those regarded as primary; c) the five constructs cluster in two factors, one including blunted affect and alogia and the other consisting of anhedonia, avolition and asociality. In this paper, for each construct, we report the current definition; highlight differences among the main assessment instruments; illustrate quantitative measures, if available, and their relationship with the evaluations based on rating scales; and describe correlates as well as experimental models. We conclude that: a) the assessment of the negative symptom dimension has recently improved, but even current expert consensus‐based instruments diverge on several aspects; b) the use of objective measures might contribute to overcome uncertainties about the reliability of rating scales, but these measures require further investigation and validation; c) the boundaries with other illness components, in particular neurocognition and social cognition, are not well defined; and d) without further reducing the heterogeneity within the negative symptom dimension, attempts to develop successful interventions are likely to lead to great efforts paid back by small rewards.
Từ khóa
Tài liệu tham khảo
Haslam J., 1809, Observations on madness and melancholy
Jackson JH., 1885, On temporary mental disorders after epileptic paroxysms, West Riding Lunatic Asylum Med Rep, 5, 105
Kraepelin E., 1919, Dementia praecox and paraphrenia
Bleuler E., 1950, Dementia praecox, or the group of schizophrenias
Goff DC., D‐cycloserine in schizophrenia: new strategies for improving clinical outcomes by enhancing plasticity, Curr Neuropharmacol
Garay RP, 2016, Therapeutic improvements expected in the near future for schizophrenia and schizoaffective disorder: an appraisal of phase III clinical trials of schizophrenia‐targeted therapies as found in US and EU clinical trial registries, Expert Opin Pharmacother, 19, 1
Kelley ME, 1999, Empirical validation of primary negative symptoms: independence from effects of medication and psychosis, Am J Psychiatry, 156, 406, 10.1176/ajp.156.3.406
Andreasen NC., 1984, The Scale for the Assessment of Negative Symptoms (SANS)
Ekman P, 1978, Facial Action Coding System: investigator's guide
Wolf K, 2004, The influences of olanzapine on facial expression of emotions in schizophrenia – an improved facial EMG study, German J Psychiatry, 7, 14
Tremeau F., 2006, A review of emotion deficits in schizophrenia, Dialogues Clin Neurosci, 8, 59, 10.31887/DCNS.2006.8.1/ftremeau
Lavelle M, 2013, Is nonverbal communication disrupted in interactions involving patients with schizophrenia? Schizophr, Bull, 39, 1150
Meehl PE., 1975, Hedonic capacity: some conjectures, Bull Menninger Clin, 39, 295
Eckblad ML, 1982, The Revised Social Anhedonia Scale
Cannon M, 1997, Premorbid social functioning in schizophrenia and bipolar disorder: similarities and differences, Am J Psychiatry, 154, 1544
Kaiser S, Individual negative symptoms and domains – Relevance for assessment, pathomechanisms and treatment, Schizophr Res
Myin‐Germeys I, 2000, Schizophrenia patients are more emotionally active than is assumed based on their behavior. Schizophr, Bull, 26, 847
O'Doherty J., 2016, Multiple systems for the motivational control of behavior and associated neural substrates in humans, Curr Top Behav Neurosci, 291
Reddy LF, 2015, Effort‐based decision‐making paradigms for clinical trials in schizophrenia: Part 1 – Psychometric characteristics of 5 paradigms. Schizophr, Bull, 41, 1045